NCT05978908View on ClinicalTrials.gov

Phase1 First in Human Ascending Dose Study to Evaluate the Safety and Tolerability of FC-12738 in Health Adults

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 20, 2024

Primary Completion Date

June 3, 2024

Study Completion Date

June 28, 2024

Conditions

Safety IssuesTolerance

Interventions

DRUG

FC-12738

Retro enversio pentapeptide of thymopentin

DRUG

Saline

placebo

Trial Locations (1)

08009

Hassman Research Inc, Berlin

All Listed Sponsors

lead

Neurodegenerative Disease Research Inc

OTHER

NCT05978908 - Phase1 First in Human Ascending Dose Study to Evaluate the Safety and Tolerability of FC-12738 in Health Adults | Biotech Hunter | Biotech Hunter